US2017137430A1PendingUtilityA1
Nuclear Transport Modulators And Uses Thereof
Assignee: KARYOPHARM THERAPEUTICS INCPriority: Jul 29, 2011Filed: Jul 22, 2016Published: May 18, 2017
Est. expiryJul 29, 2031(~5 yrs left)· nominal 20-yr term from priority
Inventors:Vincent P. SandanayakaSharon ShachamMichael KauffmanSharon ShechterDilara MccauleyYosef LandesmanWilliam SenapedisJean-Richard Sanit-Martin
A61P 43/00A61P 35/00A61P 31/12A61P 29/00A61P 13/12C07D 403/06C07D 401/14C07D 401/06C07D 403/12C07D 405/14C07D 213/50C07D 401/12C07D 403/14C07D 487/10C07D 413/12C07D 249/08C07D 401/08Y02E10/549
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
Claims
exact text as granted — not AI-modified1 . A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Ring A is an optionally substituted ring selected from phenyl, an 8-10 membered bicyclic aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
Ring B is an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aryl ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
X is selected from 0, S, N—CN, and NR;
R is hydrogen or an optionally substituted group selected from C 1-6 aliphatic, 3-8 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, phenyl, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
Y is a covalent bond or an optionally substituted bivalent C 1-4 hydrocarbon group, wherein one methylene unit of Y is optionally replaced by —O—, —S—, —N(R 6 )—, —C(O)—, —C(S)—, —C(O)N(R 6 )—, —N(R 6 )C(O)N(R 6 )—, —N(R 6 )C(O)—, —N(R 6 )C(O)O—, —OC(O)N(R 6 )—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R 6 )—, —N(R 6 )S(O) 2 —, —OC(O)— or —C(O)O—;
each of R 1 and R 2 is independently hydrogen or an optionally substituted group selected from C 1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aryl ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
R 1 and R 2 are taken together with their intervening atoms to form a 4-8 membered saturated, partially unsaturated, or aromatic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the ring formed thereby is substituted with —(R 5 ) p ;
each of n, m, and p is independently an integer selected from 0, 1, 2, 3 and 4;
q is an integer selected from 0, 1 and 2;
each of R 3 , R 4 , and R 5 is independently halogen, —NO 2 , —CN, —N 3 , -L-R 6 , or an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aryl ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
two R 3 groups on Ring B are taken together with their intervening atoms to form a fused 4-8 membered saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or:
two R 4 groups on Ring A are taken together with their intervening atoms to form a fused 4-8 membered saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or:
two R 5 groups on the ring formed by R 1 and R 2 are taken together with their intervening atoms to form a fused 4-8 membered saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
L is a covalent bond or an optionally substituted bivalent C 1-6 hydrocarbon group, wherein one or two methylene units of L is optionally and independently replaced by -Cy-, —O—, —S—, —N(R 6 )—, —C(O)—, —C(S)—, —C(O)N(R 6 )—, —N(R 6 )C(O)N(R 6 )—, —N(R 6 )C(O)—, —N(R 6 )C(O)O—, —OC(O)N(R 6 )—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R 6 )—, —N(R 6 )S(O) 2 —, —OC(O)— or —C(O)O—;
-Cy- is an optionally substituted bivalent ring selected from a 3-7 membered saturated or partially unsaturated cycloalkylenylene ring, a 4-7-membered saturated or partially unsaturated heterocycloalkylene ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, phenylene, a 5-6 membered monocyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic arylene, and an 8-10 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and
each R 6 is independently hydrogen or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, an 8-10 membered bicyclic saturated, partially unsaturated or aryl carbocyclic ring, a 4-7-membered saturated or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or:
two R 6 on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or aromatic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur,
provided the compound is not (Z)-3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)-N-cyclopentylacrylamide, (Z)-1-(azetidin-1-yl)-3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)prop-2-en-1-one, (Z)-3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3-difluoroazetidin-1-yl)prop-2-en-1-one, (Z)-1-(3,3-difluoroazetidin-1-yl)-3-(3-(3-methoxy-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)prop-2-en-1-one, (Z)-1-(3,3-difluoroazetidin-1-yl)-3-(3-(3-isopropoxy-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)prop-2-en-1-one, (Z)-3-(5-(3-chlorophenyl)-4H-1,2,4-triazol-3-yl)-N-phenylacrylamide, (Z)-3-(5-(3-chlorophenyl)-4H-1,2,4-triazol-3-yl)-N-methyl-N-phenylacrylamide, (E)-tert-butyl (4-(3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)acrylamido)phenyl)carbamate, (E)-3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)-N-(4-methoxyphenyl)acrylamide, (E)-N-(3-chlorophenyl)-3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)acrylamide, (E)-N-(4-aminophenyl)-3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)acrylamide, (Z)-3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)-N-isopropyl-N-methylacrylamide, (Z)-3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)-N-fluoro-N-isopropylacrylamide, (Z)-3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)acrylamide, (E)-3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)-N-phenylacrylamide, (E)-3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)-N-methyl-N-phenylacrylamide, (E)-3-(3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl)acrylamide or (Z)-3-(3-(3-isopropoxy-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylamide.
2 . The compound according to claim 1 , wherein Ring A is an optionally substituted 5-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
3 . The compound according to claim 1 , wherein Ring A is selected from pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl and thiadiazolyl.
4 . The compound according to claim 3 , wherein Ring A is triazolyl.
5 - 7 . (canceled)
8 . The compound according to claim 3 , wherein Ring A is selected from:
9 . The compound according to claim 1 , wherein Ring A is an optionally substituted 6-membered monocyclic heteroaryl ring having 1-4 nitrogen atoms.
10 - 11 . (canceled)
12 . The compound according to claim 1 , wherein Ring B is phenyl.
13 . The compound according to claim 12 , wherein Ring B is substituted and is represented by the following structural formula:
14 . The compound according to claim 1 , wherein X is O.
15 . The compound according to claim 1 , wherein Y is a covalent bond.
16 . The compound according to claim 1 , wherein R 1 and R 2 are taken together with their intervening atoms to form a 4-8 membered saturated, partially unsaturated, or aromatic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
17 . The compound according to claim 16 , wherein the 4-8 membered saturated heterocyclic ring formed by R 1 , R 2 and their intervening atoms is represented by the following structural formula:
18 . The compound according to claim 17 , wherein p is 2.
19 . The compound according to claim 18 , wherein R 5 is —F.
20 . The compound according to claim 19 , wherein the 4-8 membered saturated heterocyclic ring formed by R 1 , R 2 and their intervening atoms is represented by the following structural formula:
21 . (canceled)
22 . The compound according to claim 1 , wherein the compound is represented by any one of the following structural formulas, or a pharmaceutically acceptable salt thereof:
Com-
pound
Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
45
46
47
48
49
50
51
53
54
55
57
59
60
61
62
63
65
66
68
69
23 . (canceled)
24 . A compound represented by structural formula (VI):
or a pharmaceutically acceptable salt thereof, wherein:
Z is selected from N, CH and C(Cl);
R 1 is hydrogen; and
R 2 is selected from —CH 2 -oxazol-5-yl, —CH 2 -pyrimidin-5-yl, —CH 2 -(1-methylpyrrolidin-3-yl), or or:
R 1 and R 2 are taken together with the nitrogen atom to which they are bound to form
4-hydroxypiperidin-1-yl, pyrrolidiny-1-yl, or azetidin-1-yl, wherein the pyrrolidiny-1-yl and azetidin-1-yl are each optionally and independently substituted at the 3-position with up to two substituents independently selected from fluoro, —CF 3 , —CH 3 , —OH, pyridin-2-yl, —CH 2 -N(CH 3 ) 2 , —CH 2 —NH—CH 3 , —CH 2 —NH 2 , —CN, —C(O)—O—CH 3 ; and
R 7 is selected from fluoro, —OH and —CF 3 .
25 . The compound according to claim 24 , wherein the compound is represented by any one of the following structural formulas, or a pharmaceutically acceptable salt thereof:
Com-
pound
Structure
51
52
53
54
56
57
58
59
60
61
63
66
26 . A composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
27 . A method for modulating CRM1, the method comprising contacting CRM1 with a therapeutically effective amount of the compound of claim 1 .
28 - 31 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.